Study Reveals Shingles Vaccine Reduces Heart Disease Risk for Several Years
Recent findings indicate that obtaining a shingles vaccine offers additional benefits beyond safeguarding against the painful skin condition; it also significantly diminishes the likelihood of heart-related illnesses.
According to a study published this week, individuals who received the shingles vaccine experienced a 23% reduction in cardiovascular episodes, such as heart attacks, strokes, and heart failure, over a period extending up to eight years.
The research analyzed data involving over one million participants aged 50 and older, gathered from 2012 onward. Results indicated that the protective benefits were more pronounced in men, those under 60, and individuals engaged in smoking, drinking, or a sedentary lifestyle.
Mechanisms Behind the Vaccine’s Protective Effect
Professor Dong Keon Yon from the Kyung Hee University College of Medicine in Seoul, who spearheaded the study, suggests that the vaccine's heart benefits could be due to its ability to prevent blood vessel damage, inflammation, and clotting—factors that can lead to cardiovascular diseases.
He elaborated that the observed benefits are more robust in younger individuals due to their heightened immune response, as well as in males, possibly owing to varying vaccine efficacy.
Vaccine Variants and Accessibility
The research focused on the live zoster vaccine, which contains an attenuated form of the virus responsible for shingles. However, the live vaccine is not suitable for certain populations, prompting some countries to transition to recombinant vaccines, which do not contain live virus.
In the United States, Shingrix, a non-live vaccine introduced in 2017 and made by GlaxoSmithKline, has superseded the one-shot live vaccine Zostavax. Shingrix boasts over 90% effectiveness in preventing shingles.
Professor Yon emphasizes the necessity for additional research on recombinant vaccines to verify if they offer similar cardiac benefits since the study does not cement a direct cause-and-effect link.
Public Health Recommendations
The Centers for Disease Control and Prevention (CDC) advise individuals 50 and older to receive a two-dose shingles vaccine to mitigate the risk of developing shingles, which is more prevalent with advancing age.
Shingles results from the herpes zoster virus, previously dormant in individuals who had chickenpox, which can reactivate later in life.
Exploring Additional Health Benefits
Previously, evidence has pointed to possible supplementary advantages of the shingles vaccination. For instance, it may delay the manifestation of dementia, a condition characterized by cognitive decline.
A separate study published in July revealed that vaccinated individuals lived longer without a dementia diagnosis compared to those who received older versions of the shingles vaccine.
Dr. Céline Gounder of CBS News underscored the versatility and accessibility of the current vaccine, given its coverage by health insurance, applauding its protective capabilities.




Leave a Reply